Deals this week: Dova Pharmaceuticals Inc, Gamida Cell Ltd, Onxeo SA

22nd June 2017 (Last Updated June 22nd, 2017 18:30)

US-based clinical-stage pharmaceutical company Dova Pharmaceuticals Inc is intending to raise between $60.93m and $69.06m through an initial public offering (IPO) of 4,062,500 shares of its common stock.

US-based clinical-stage pharmaceutical company Dova Pharmaceuticals Inc is intending to raise between $60.93m and $69.06m through an initial public offering (IPO) of 4,062,500 shares of its common stock. 

The shares are priced between $15 and $17 each, while underwriters are granted a 30-day option to purchase 609,375 additional shares to cover any over-allotment. 

Proceeds are intended to be used for the commercialisation and clinical trials for additional indications of its drug candidate, avatrombopag, while a portion of proceeds will be used for partial repayment of obligations to Eisai, and the remaining for general corporate purposes.

Gamida Cell Ltd has closed a private financing of $40m from existing and new investors.

The Israel-based cellular and immune therapies developer intends to use funds to complete the Phase III clinical trial on NiCord and to prepare for commercialisation of the product.

Part of proceeds will also be used to expand the company’s presence in the US and to continue development of additional products in the pipeline. 

"Underwriters will be granted a 30-day option to purchase additional shares worth $30m."

Onxeo SA has raised €15m ($16.7m) through the private placement of shares of its common stock to US and European institutional investors.

The placement included 3,529,411 shares priced at €4.25 ($4.75) each.

Based in France, Onxeo is a clinical-stage biotechnology company that intends to use proceeds from the placement partly to pursue development of its orphan oncology programmes, and for general corporate purposes.

US-based clinical-stage gene therapy company AveXis Inc intends to raise $200m in gross proceeds through an underwritten public offering of shares of its common stock.

Underwriters will be granted a 30-day option to purchase additional shares worth $30m.

Proceeds are intended for funding the company’s research and manufacturing activities, conducting clinical trials, and for general corporate purposes.